AMARIN CORP PLC\UK Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
AMARIN CORP PLC\UK (AMRN) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $1.37 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-02
- AMARIN CORP PLC\UK effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was $1.37M, a 4332.26% increase from fiscal 2023.
- AMARIN CORP PLC\UK effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was $31.00K, a 98.68% decline from fiscal 2022.
- AMARIN CORP PLC\UK effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $2.34M, a 55.34% decline from fiscal 2021.
- AMARIN CORP PLC\UK effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2021 was $5.25M, a 14.26% decline from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2024-12-31 | $1.37M 10-K · filed 2026-03-02 |
| 2023-12-31 | $31.00K 10-K · filed 2026-03-02 |
| 2022-12-31 | $2.34M 10-K · filed 2025-03-12 |
| 2021-12-31 | $5.25M 10-K · filed 2024-02-29 |
| 2020-12-31 | $6.12M 10-K · filed 2023-03-01 |
| 2019-12-31 | $5.47M 10-K · filed 2022-03-01 |
| 2018-12-31 | $3.06M 10-K · filed 2021-02-25 |
| 2017-12-31 | $1.67M 10-K · filed 2020-02-25 |
| 2016-12-31 | $1.16M 10-K · filed 2019-02-27 |
| 2015-12-31 | $808.00K 10-K · filed 2018-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |